CSBio CSBio

X
[{"orgOrder":0,"company":"PolyActiva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poly Activa Completes Initial Clinical Trial with Latanoprost FASR Ocular Implant Delivering Glaucoma Treatment to Patients Over a Six-Month Period","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PolyActiva"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PolyActiva"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Phase IIa study met primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort, demonstrating a potential significant benefit of the PA5108 Ocular Implant designed to treat patients with glaucoma by enabling a constant dose of medication.

            Lead Product(s): Latanoprost

            Therapeutic Area: Ophthalmology Product Name: PA5108

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Latanoprost FA SR Ocular Implant is designed to provide a constant daily therapeutic dose of latanoprost free acid (the active ingredient of a commonly prescribed glaucoma eye-drop, Xalatan®) for 6-months.

            Lead Product(s): Latanoprost

            Therapeutic Area: Ophthalmology Product Name: Xalatan

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY